Shanghai Yingli Pharmaceutical
Shanghai Yingli Pharmaceutical developed linperlisib, the PI3K-delta inhibitor approved in China in 2022 for relapsed follicular lymphoma.
Overview
Shanghai Yingli Pharmaceutical is a small-molecule company in Shanghai's Zhangjiang science park. Its PI3K-delta inhibitor linperlisib (YY-20394) received conditional NMPA approval in November 2022 for relapsed or refractory follicular lymphoma after two or more lines, and is in trials in peripheral T-cell lymphoma and solid tumours.
Scorecard
All companies- approved products +6
- modalities +2
- regions +1
Similar pages
not linked directly; found by shared links- TrialALTER 0303
Shares Small-molecule kinase inhibitors and the tag china.
- TreatmentIcotinib
Shares Small-molecule kinase inhibitors and the tag china.
- TrialZGDH3 (donafenib vs sorafenib)
Shares Small-molecule kinase inhibitors and the tag china.
- TrialAENEAS
Shares Small-molecule kinase inhibitors and the tag china.
- TreatmentFulzerasib
Shares Small-molecule kinase inhibitors and the tag china.
- TreatmentRelmacabtagene autoleucel
Shares Follicular lymphoma and the tag china.
- TrialFURLONG
Shares Small-molecule kinase inhibitors and the tag china.
- TreatmentDonafenib
Shares Small-molecule kinase inhibitors and the tag china.